LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of $31.00.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors surrounding Liquidia Technologies’ current legal and regulatory situation. Despite a recent court decision favoring United Therapeutics, which maintains exclusivity for Tyvaso DPI until May 2025, Jubinville views this outcome as ultimately beneficial for Liquidia. The decision aligns with expectations for Yutrepia’s transition from tentative to full approval around the same timeframe, suggesting a clear path forward for Liquidia’s product launch.
Moreover, the judge’s deference to the FDA’s interpretation of its policies could bode well for Liquidia in ongoing legal matters, potentially favoring their amended NDA for Yutrepia. Although the recent ruling did not accelerate commercialization, the anticipated timeline remains intact, supporting a positive outlook for Liquidia’s market entry. These factors collectively underpin Jubinville’s confidence in Liquidia’s strategic position and future prospects, justifying the Buy rating.
According to TipRanks, Jubinville, PhD is an analyst with an average return of -6.2% and a 32.81% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, Liquidia Technologies, and Tarsus Pharmaceuticals.
Questions or Comments about the article? Write to editor@tipranks.com